



Decision number: CCH-D-0000001260-89-04/F

Helsinki, 20 December 2010

**DECISION ON A COMPLIANCE CHECK OF A REGISTRATION PURSUANT TO ARTICLE 41(3) OF REGULATION (EC) NO 1907/2006****Substance S190700, CAS [REDACTED] (EC No. 443-510-2), Registration Number: [REDACTED]****Addressee:** [REDACTED]**I. Procedure**

Pursuant to Article 41(1) of Regulation (EC) No 1907/2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (the REACH Regulation) the European Chemicals Agency (ECHA) has performed a compliance check of the registration dossier for S190700, CAS No. [REDACTED] (EC No. 443-510-2 [REDACTED])

[REDACTED] (the "Registrant"), latest submission number [REDACTED], for [REDACTED]

Following the tonnage band update to [REDACTED] per year for a substance that was previously notified pursuant to Directive 67/548/EEC, the registrant is according to Article 24(2) of the REACH Regulation obliged to submit the additional required information corresponding to the reached tonnage threshold, as well as to all lower tonnage thresholds, in accordance with Articles 10 and 12 of the REACH Regulation.

The present compliance check was initiated on 24 September 2009.

The draft decision on the basis of the compliance check was sent to the Registrant for comments on 12 April 2010. ECHA has taken the comments provided by the Registrant on 11 May 2010 into account and has amended the statement of reasons of this draft decision accordingly.

On 11 June 2010 ECHA notified the competent authorities of the Member States of its draft decision and invited them pursuant to Article 51(1) of the REACH Regulation to submit proposals to amend the draft decision within 30 days.

By 11 July 2010 ECHA did not receive any proposals for amendments from the competent authorities of the Member States.

This compliance check decision does not prevent ECHA to initiate further compliance checks on the present dossier at a later stage.

## II. Information required

ECHA has taken the following decision in accordance with the procedure set out in Articles 50 and 51 of the REACH Regulation.

1. Pursuant to Articles 41(1)(a), 41(3) and 10(a)(ii) as well as Annex VI, Section 2.1.4 of the REACH Regulation, the Registrant shall submit the CAS name for the registered substance in the appropriate IUCLID field of the substance dataset (IUCLID Section 1.1).
2. Pursuant to Articles 41(1)(a), 41(3), [REDACTED] and 13(1) as well as Annex VIII, Section 8.7.1. of the REACH Regulation, the Registrant shall submit information on reproductive/developmental toxicity using the test method of screening for one species, guideline OECD 421 or 422.
3. Pursuant to Articles 41(1)(a), 41(3), 10(a)(vii), 3(28) and 111 of as well as Sections 1.1.4. and 3.1.5. of Annex I to the REACH Regulation, the Registrant shall provide in the IUCLID format a robust study summary of the following studies provided under the following provisions of the REACH Regulation and IUCLID sections:
  - Annex VIII, Section 9.2.2.1 (IUCLID Section 5.1.2): study named<sup>1</sup> *Hydrolysis.001*;
  - Annex VII, Section 9.2.1.1 (IUCLID Section 5.2.1): a robust study summary is requested to be provided at least for the study that was used to draw the conclusions on the endpoint, i.e. either the study named *Biodegradation in water screening tests SNIF#001-5.2.11-0* or the study named *Biodegradation in water screening tests.002*;
  - Annex VIII, Section 9.3.1 (IUCLID Section 5.4.1): study named *Adsorption / desorption.001*. In particular, the robust study summary is requested to include sufficient information to conclude about the logK<sub>oc</sub> in the pH range of agricultural soil and sewage in treatment plants tanks (pH 5,5-7,5);
  - Annex VIII, Section 9.1.3 (IUCLID Section 6.1.1): study named *Short-term toxicity to fish, SNIF#001-5.1.01-01*;
  - Annex VII, Section 9.1.1 (IUCLID Section 6.1.3): study named *Short-term toxicity to aquatic invertebrates, SNIF#001-5.1.02-01*;
  - Annex VIII, Section 9.1.4 (IUCLID Section 6.1.7): study named *Toxicity to microorganisms.001*;
  - Annex VII, Section 8.4.1 (IUCLID Section 7.6.1): a robust study summary is requested to be provided at least for the study that was used to draw the conclusions on the endpoint, i.e. either *Genetic toxicity in vitro SNIF#001-4.3.10-01*, or *Genetic toxicity in vitro SNIF#001-4.3.10-02*;
  - Annex VIII, Section 8.4.2 (IUCLID Section 7.6.1): study named *Genetic toxicity in vitro SNIF#001-4.3.21-01*; and
  - Annex VIII, Section 8.4.3 (IUCLID Section 7.6.1): study named *Genetic toxicity in vitro 004*.

---

<sup>1</sup> This is the name of the study in IUCLID. When the study was migrated from a previous SNIF file, a name was automatically generated with the code SNIF#.



Pursuant to Article 41(4) of the REACH Regulation, the Registrant shall submit the information in the form of an updated IUCLID dossier to ECHA by 12 months from the date of the decision.

### III. Statement of reasons

Based on the examination of the technical dossier, ECHA concludes that the information therein submitted by the Registrant for registration of the above mentioned substance in accordance with Article 6 of the REACH Regulation, does not comply with the requirements of Articles 10, 12, 13 and 111 and with Annexes I, VI to VIII and XI thereof. Consequently, the Registrant is requested to submit the information required above that is needed to bring the registration into compliance with the relevant information requirements.

#### 1) Missing information on substance identity

Pursuant to Article 10(a)(ii) and Annex VI, Section 2 of the REACH Regulation, the technical dossier of the registration shall include information on the identity of the substance. Annex VI, Section 2 lists information requirements that shall be sufficient to identify the registered substance.

According to Annex VI, Section 2.1.4. of the REACH Regulation, CAS name and CAS number shall be provided, if available. The Registrant does not report the CAS name in the appropriate IUCLID field (that is IUCLID Section 1.1), although it can be found in the analytical report attached to IUCLID Sections 1-4.

Therefore, the Registrant is required to report the CAS name in the IUCLID Section 1.1.

#### 2) Missing information on screening for reproductive/developmental toxicity

Pursuant to Article [REDACTED] of the REACH Regulation, a registration for a substance manufactured or imported in quantities of [REDACTED] per year shall contain as a minimum the information specified in Annexes VII [REDACTED] of the REACH Regulation.

A screening study for reproductive/developmental toxicity, one species (OECD 421 or 422) is a standard information requirement for registrations in the [REDACTED] range pursuant to Annex VIII, column 1 of Section 8.7.1.

The Registrant has omitted the screening study in question with a reference to exposure based waiving according to Annex XI, Section 3.

According to Article 13(1) of and Section 3 of Annex XI to the REACH Regulation (as amended by Commission Regulation (EC) No 134/2009), testing in accordance with Section 8.7. of Annex VIII may be omitted based on a thorough and rigorous exposure assessment, provided that any one of the three criteria of Section 3 of Annex XI are met and that adequate justification and documentation are submitted.

The first criterion (3.2(a)) requires "absence of or no significant exposure in all scenarios of the manufacture and all identified uses". Moreover, relevant PNECs or DNELs are to be derived and exposure results are to be well below the derived PNECs or DNELs.



The second criterion (3.2(b)) requires "throughout the life cycle strictly controlled conditions as set out in Article 18(4)(a) to (f)".

The third criterion (3.2(c)) sets out conditions which have to be fulfilled for a substance incorporated in an article in which it is permanently embedded in a matrix or otherwise rigorously contained by technical means.

In the registration dossier, the Registrant has not indicated, which of these criteria he is using for waiving the testing for reproductive/developmental toxicity. Instead, the Registrant has included in the dossier an exposure assessment by which he claims that a relevant human exposure can be excluded.

ECHA has analysed the exposure scenarios and risk characterisation contained in the registration dossier and makes the following observations:

- Strictly controlled conditions as set out in Article 18(4)(a) to (f) are not demonstrated and therefore criterion 3.2(b) for exposure-based waiving is not satisfied. In particular, conditions (a), (c) and (f) set out in Article 18(4) do not appear to be fulfilled for the consumer use [REDACTED]. This is because it has not been shown that the substance is rigorously contained by technical means during its whole lifecycle (condition a), is not handled by trained and authorised personnel only (condition c), and substance-handling procedures are not well documented and strictly supervised by the site operator (condition f).
- In addition to the main observation above, estimated exposure levels are beyond insignificant and therefore either criteria for 3.2 (a) and 3.2(b) for exposure-based waiving are not satisfied. This is because
  - An indication of significant exposure can be observed in Table 75 concerning the risk characterisation of long-term systemic effects for workers. From the reported values it appears that, when calculated over the 2 hours of filling task, inhalation exposure accounts for 90% of DNEL; when averaged over the year, the exposure to combined inhalation and dermal routes account for ca. 14 % of DNEL.
  - Insignificant exposure for consumer use has not been demonstrated. In the exposure scenario for consumer use (ES2), a sub-scenario of accidental oral exposure of small children is described. This exposure scenario has not been covered in the risk characterisation (oral exposure of consumers is not considered under section 10.2.1.1 of the chemical safety report, as required by Annex I, Section 10.2.1.2). It has only been addressed in the exposure section, where the exposure is compared with the NOAEL (divided by one assessment factor, 10), whereas the evaluation of exposure requires a comparison with the appropriate DNEL (Annex I, Section 6.3) in the risk characterisation section.
- The third criteria (3.2(c)) concerns the substance incorporated in an article. Since [REDACTED] not an article within the meaning of Article 3(3) of the REACH Regulation, and the substance is not permanently embedded in it, this criterion does not apply to this case.

For these reasons, ECHA concluded that the justification provided by the Registrant for waiving the concerned test does not fulfill the criteria set out in Annex XI, Section 3.



The Registrant received the draft decision for comments on 12 April 2010 and provided the following comments on 11 May 2010, in brief:

- The study was omitted on the basis of criterion 3.2(a) of section 3 of Annex XI.
- The estimation for human exposure during manufacture is based on internal company hazard banding under the UK Control of Substances Hazardous to Health (COSHH) regulations. In practice exposure will be much lower as the plant is required to operate to significantly higher levels of control to allow for the handling of other more hazardous substances. Therefore, the Registrant proposes that in lieu of the reproductive/developmental screen he undertakes on plant task based measurements to confirm the actual true extent of inhalation exposure to S190700 during its manufacture. He expects that measured values will confirm that human exposure is well below the DNEL and that no significant exposure to S190700 during manufacture occurs.
- Concerning the consumer exposure, the Registrant states that he will update the child oral exposure scenario so that more realistically reflects accidental/incidental child exposure and meets the requirements of Annex I, section 6.3. In addition, the risk characterisation will be completed with inclusion of this scenario.

In response to the proposal of the Registrant to refine the exposure assessment based on monitoring data, ECHA clarifies that, according to Annex XI, 3.2. (a), all three conditions (i), (ii) and (iii) need to be met:

- **Condition (i)** requires to demonstrate the absence of or no significant exposure throughout the life cycle of the substance. This condition is not met by the dossier; because the Registrant has informed ECHA of his intention to provide more robust exposure assessment including measurement, but the information is presently not available.
- **Condition (ii)** concerns the derivation of a relevant and appropriate DNEL. This condition is not met because the relevant DNEL for reproductive toxicity cannot be derived from the 28-day repeated dose toxicity study, because that study does not cover the reproductive endpoints and parameters, which are covered in a screening study (OECD 421 or 422). In other words, contrary to condition (ii), the DNEL used by the Registrant cannot be considered as relevant and appropriate to the information requirement suggested to be omitted and for risk assessment purposes.
- **Condition (iii)** concerns the comparison of the derived DNEL with the results of the exposure assessment. This condition is not met because there is no DNEL from a reproductive toxicity study. Therefore a comparison of a relevant DNEL and the exposure cannot be done.

Concerning the relevance of available information with respect to the reproductive/developmental toxicity, the Registrant indicates the following justification in the CSR (i.e. not in his comment) (underlining added): "Water soluble [redacted] as a class exhibits low toxicological activity and are rapidly excreted from the body which mitigates the potential for any adverse toxicity to occur for endpoints not covered by the currently available test data set. In a 28-day repeated dose oral toxicity study conducted on S190700 no changes were seen in the reproduction related tissues of the epididymides, seminal vesicles or ovaries. There are no reports in the literature of reproductive and developmental toxicity with substance similar in structure to S190700 [redacted] are not a class of compound that are alerting for reproductive toxicity."

ECHA specifies that (i) water solubility and rapid excretion are not valid waiving arguments according Annex XI or Annex VIII, 8.7.1, (ii) parameters covered in the 28-day study do not



correspond with the scope of a screening study of fertility (OECD 421 or 422), which encompasses several other additional fertility endpoints and parameters and is a standard REACH requirement for this tonnage band; (iii) the proposed read-across from other [REDACTED] does not specify the studies on [REDACTED] from which the read-across information was obtained. Moreover, the suggested read-across is not documented as required by Annex XI, 1.5. Therefore, ECHA concludes that these justifications are not valid for waiving the standard information requirement for reproductive toxicity and do not include information that can be used for deriving a relevant DNEL for reproductive/developmental toxicity in the scope of condition (ii) of Annex XI, 3.2. (a).

In conclusion, none of the conditions under Annex XI 3.2 (a) are met and therefore waiving/adaptation of the information requirement for screening studies OECD 421/422 as according to the Annex VIII, 8.7.1, cannot be accepted.

**Therefore, the Registrant is requested to provide information on reproductive/developmental toxicity using the test method of screening for one species, guideline OECD 421 or 422.**

### 3) Lack of robust study summaries

According to Articles 10(a)(vii) and 111 of and Sections 1.1.4 and 3.1.5 of Annex I to the REACH Regulation, a technical dossier that is in the IUCLID format shall include robust study summaries of all key data used in the human health and environmental hazard assessment. Under Article 3(28), the robust study summary shall include a "detailed summary of the objectives, methods, results and conclusions of a full study report providing sufficient information to make an independent assessment of the study minimising the need to consult the full study report."

The Registrant has not reported in the IUCLID format robust study summaries within the meaning of Article 3(28) of the REACH Regulation for the following studies provided under the following provisions of the REACH Regulation and IUCLID sections:

- Hydrolysis as a function of pH (Annex VIII, Section 9.2.2.1; IUCLID Section 5.1.2). In particular, the description of test conditions and test design are missing;
- Ready biodegradability (Annex VII, Section 9.2.1.1; IUCLID Section 5.2.1). A robust study summary is requested to be provided at least for the study that was used to draw the conclusions on the endpoint, i.e. either the study named *Biodegradation in water screening tests SNIF#001-5.2.11-0* or the study named *Biodegradation in water screening tests.002*. In particular, details of the inoculum, the description of test conditions (e.g. temperature, pH) and indication of the fulfilment of validity criteria are missing;
- Adsorption/desorption screening (Annex VIII, Section 9.3.1; IUCLID Section 5.4.1). Details on the operating conditions, the reference substances and indication of the fulfilment of validity criteria are missing. Moreover, the Registrant reports the results of the HPLC test (OECD 121) conducted at pH 2 (logKoc is > 5.0) and at pH 10 (logKoc is <1.5). There is a very large difference between the logKoc measured at pH 2 and pH 9. Limiting the reporting to the values measured at pH 2 and pH 9 is not sufficient information within the meaning of Article 3(28) for predicting the adsorption of the substance at pH typical of agricultural soil and sewage sludge (pH 5,5-7,5). Therefore, the robust study summary to be provided for the adsorption/desorption screening test is requested to also include sufficient information to conclude about



the logK<sub>oc</sub> in the pH range of agricultural soil and sewage in treatment plants tanks (pH 5,5-7,5). From the Registrant's comments received on 11 May 2010, it appears that a second screening study on adsorption/desorption will be commissioned to cover the pH range 5.5 – 7.5. ECHA acknowledges the Registrant's intention to perform another study on this endpoint.

- Short-term toxicity testing on fish (Annex VIII, Section 9.1.3; IUCLID Section 6.1.1). In particular, details of test conditions (e.g. dissolved oxygen, pH, temperature), details of the test design and indications of the fulfilment of validity criteria are missing;
- Short term toxicity testing on invertebrates (Annex VII, Section 9.1.1; IUCLID Section 6.1.3). In particular, details of test conditions (e.g. dissolved oxygen, pH, test temperature) and indications of the fulfilment of validity criteria are missing;
- Activated sludge respiration inhibition testing (Annex VIII, Section 9.1.4; IUCLID Section 6.1.7). In particular, details of the test system (e.g. concentration of the activated sludge), of the test conditions (e.g. temperature) and indications of the fulfilment of validity criteria are missing;
- Mutagenicity, *in vitro* gene mutation study in bacteria (Annex VII, Section 8.4.1; IUCLID Section 7.6.1). In particular, positive control is not specified and the information on doses per plate are not indicated, and information on frequency of the revertant colonies per dose is missing. A robust study summary is requested to be provided at least for the study that was used to draw the conclusions on the endpoint, i.e. either *Genetic toxicity in vitro* SNIF#001-4.3.10-01, or *Genetic toxicity in vitro* SNIF#001-4.3.10-02;
- Mutagenicity, *in vitro* cytogenicity study in mammalian cells (Annex VIII, Section 8.4.2; IUCLID Section 7.6.1). In particular, positive control is not specified, information on doses per unit of the culture medium are not indicated, and information on percentages of cells with structural chromosome aberrations per dose is missing;  
and
- Mutagenicity, *in vitro* gene mutation study in mammalian cells (Annex VIII, Section 8.4.3; IUCLID Section 7.6.1). In particular, mutant frequency per test concentration is missing.

Therefore, the Registrant is required to provide robust study summaries of all studies listed above in the IUCLID format. Further guidance can be found in the *Information requirements Manual 1 Requirements for Robust Study Summary* published on the website at: [http://echa.europa.eu/doc/publications/practical\\_guides/pg\\_report\\_robust\\_study\\_summaries.pdf](http://echa.europa.eu/doc/publications/practical_guides/pg_report_robust_study_summaries.pdf).

#### **IV. General requirements for the generation of information and Good Laboratory Practice**

ECHA always reminds registrants of the requirements of Article 13(4) of the REACH Regulation that reads:

*“Ecotoxicological and toxicological tests and analyses shall be carried out in compliance with the principles of good laboratory practice provided for in Directive 2004/10/EC or other international standards recognised as being equivalent by the Commission or the Agency and with the provisions of Directive 86/609/EEC, if applicable.”*

According to Article 13(3) of the REACH Regulation, tests that are required to generate information on intrinsic properties of substances shall be conducted in accordance with the test methods laid down in a Commission Regulation or in accordance with other international test methods recognised by the Commission or the European Chemicals Agency as being appropriate. Thus, the registrant shall refer to Commission Regulation (EC) No 440/2008 laying down test methods pursuant to Regulation (EC) No 1907/2006 adapted to the technical progress by Commission Regulation (EC) No 761/2009 and use the applicable test methods to generate the information on the endpoints indicated above.

National authorities monitoring good laboratory practice (GLP) maintain lists of test facilities indicating the relevant areas of expertise of each facility.

#### **V. Information on right to appeal**

An appeal may be brought against this decision to the Board of Appeal of ECHA under Article 51(8) of the REACH Regulation. Such an appeal shall be lodged within three months of receiving notification of this decision. Further information on the appeal procedure can be found on ECHA's internet page at [http://echa.europa.eu/appeals/app\\_procedure\\_en.asp](http://echa.europa.eu/appeals/app_procedure_en.asp). The notice of appeal will be deemed to be filed only when the appeal fee has been paid.

Done at Helsinki,

A large black rectangular redaction box covering the signature area of the document.

Geert Dancet  
Executive Director